Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XTUN:SIPHA's Equity-to-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.61 * Ranked among companies with meaningful Equity-to-Asset only.
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Equity-to-Asset Related Terms
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Equity-to-Asset Chart
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Annual Data
Trend
Equity-to-Asset
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Semi-Annual Data
Equity-to-Asset
XTUN:SIPHA vs BIEI, PTXTQ, INQD: Equity-to-Asset Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Equity-to-Asset vs Drug Manufacturers Industry
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA) has a Equity-to-Asset of 0.00 as of . 20. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Societe des Industries Pharmaceutiques de Tunisie-S I PHA T and its competitors.
Is Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's Equity-to-Asset too high?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's current Equity-to-Asset is 0.00. Overall, Societe des Industries Pharmaceutiques de Tunisie-S I PHA T has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's Equity-to-Asset compare to BIEI and PTXTQ?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's Equity-to-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median Equity-to-Asset is 0.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Societe des Industries Pharmaceutiques de Tunisie-S I PHA T and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's current Equity-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Societe des Industries Pharmaceutiques de Tunisie-S I PHA T stock overvalued right now?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA) has a current Equity-to-Asset of 0.00. The current Equity-to-Asset is 0.00. Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA), the current Equity-to-Asset is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T is a Tunisia-based company mainly engaged in manufacturing and distributing medicines and drugs. The company also has its own research and development process to develop generic drugs. It offers pharmaceutical, dietary, hygiene, and cosmetic products in dry, liquid and pasty forms.
12GF Score
Get the complete analysis for XTUN:SIPHA
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTUN:SIPHA has been successfully added to your 
